Just caught Smith & Nephew's latest earnings and the numbers are pretty solid. The medical tech company saw profit before tax jump to $779 million from $498 million year-over-year, which is a decent jump. Revenue hit $6.16 billion, up 6.1 percent, with organic growth at 5.3 percent - not explosive but steady.

What stood out to me was the margin improvement. Trading profit climbed 15.5 percent to $1.21 billion and the margin expanded 160 basis points to 19.7 percent. That's the kind of operational efficiency improvement that usually signals good management execution. EPS grew to 71.6 cents from 47.0 cents, and adjusted EPS came in at 102.0 cents versus 84.3 cents prior year.

The board is also increasing the dividend - final payout of 24.1 cents per share, up from 23.1 cents. Total annual distribution is 39.1 cents, a 4.3 percent bump. Companies don't usually raise dividends unless they're confident about cash flow, so that's a decent signal.

Looking at their guidance, they're expecting around 7.8 percent revenue growth for fiscal 2026, with underlying growth accelerating to around 6 percent. Trading profit growth on an organic basis should hit around 8 percent despite some headwinds. They've also laid out targets for fiscal 2028 with significant acceleration planned. For a large-cap medical device play, this kind of consistent execution is what you want to see from a company like Smith & Nephew.